
Veru: An oncology biopharmaceutical firm innovating novel treatments for prostate and breast cancers.
Veru, founded as an oncology biopharmaceutical company, aims to innovate novel treatments for prostate and breast cancers. The company's mission is to develop and commercialize high-quality therapies that address significant medical needs, including weight loss and viral-related ARDS. Veru's core products include a selective androgen receptor modulator (SARM) designed to mitigate muscle loss in patients undergoing weight loss therapy with GLP- drugs.
Notable individuals affiliated with Veru include its leadership team, composed of experienced professionals in the biopharmaceutical industry. The company has garnered investment from key stakeholders committed to advancing oncology treatments. Veru's significant achievements include the development of promising therapies that have the potential to transform cancer treatment paradigms. Its impact is marked by a commitment to improving patient outcomes in oncology and related fields.

Verastem

Verrica Pharmaceuticals
verrica.com

Revolution Medicines
revmed.com

Vero Biotech
vero-biotech.com

Vyriad
vyriad.com

Verseau Therapeutics
verseautx.com

Veralox Therapeutics
veralox.com

Clovis Oncology

OnCusp Therapeutics
oncusptx.com

Verda Bio
verdabio.com

Novocure
novocure.com

Elevar Therapeutics

Verix Health

ReveraGen BioPharma
reveragen.com

Veracyte
veracyte.com
Companies similar to Veru include Verastem, Verrica Pharmaceuticals, Revolution Medicines and Vero Biotech.
Veru was founded in 2016.
Veru's headquarters is located in Miami, FL, US.
Veru's most recent funding round was for $33M (USD) in December 2023.
As of Dec 14, 2023, Veru has raised a total of $133M (USD).
Veru has 375 employees as of Feb 6, 2024.